PCM
PTGX icon

Penserra Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Penserra Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,429
Closed -$117K – 1113
2025
Q1 		$117K Buy
+2,429
New +$102K ﹤0.01% 785
2021
Q4 		– Sell
-1,090
Closed -$19K – 1508
2021
Q3 		$19K Buy
1,090
+90
+9% +$3.84K ﹤0.01% 1256
2021
Q2 		$44K Buy
1,000
+30
+3% +$990 ﹤0.01% 1035
2021
Q1 		$25K Buy
970
+90
+10% +$2.28K ﹤0.01% 931
2020
Q4 		$17K Buy
880
+564
+178% +$12.1K ﹤0.01% 871
2020
Q3 		$6K Buy
+316
New +$5.93K ﹤0.01% 855

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's PTGX Position: Q2 2025 in Review

Penserra Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 2,429 shares — an estimated $117K sold.

Penserra Capital Management first reported a position in PTGX in Q3 2020 and held it in 6 quarters. The position peaked at $117K in Q1 2025. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Penserra Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Penserra Capital Management sold 2,429 Protagonist Therapeutics shares in Q2 2025, an estimated $117K.
  • Penserra Capital Management first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 6 quarters.
  • Penserra Capital Management's Protagonist Therapeutics position peaked at $117K in Q1 2025.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Penserra Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.